W. L. Gore & Associates, Inc. (Gore) today announced that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for commercial distribution for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System..
Gecko Biomedical, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, has announced it will change the company name to TISSIUM as part of an overall rebranding of the company.
Chiropractors and even some medical doctors are now running scams where they claim that fetal birth products like amniotic fluid (i.e. baby urine), placental, umbilical, and Wharton's jelly contains millions of live fetal stem cells.
Vytronus, Inc., a privately held medical device company developing novel technologies for the treatment of cardiac arrhythmias, announced today that its early feasibility study of automated ultrasound technology for the treatment of persistent atrial fibrillation recently passed the midpoint in patient enrollment and is on track for completion of enrollment in mid-2019.
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced it has received CE Mark for Ortho's VITROS® XT MicroSlide, a new multi-test technology that allows labs to run two tests simultaneously.
A study published today in the journal Nature provides a deeper understanding of why pancreatic cancer spread, or metastasis, is most commonly found in the liver.
Just 12 months after opening its doors, New U Life announced it sold more than 500,000 bottles of its innovative SOMADERM Gel in 2018. Hitting this significant milestone reflects the passion of its hardworking distributors and the leadership of Founder and Formulator Alexy Goldstein.
Merck, a leading science and technology company and leader in genome editing, today announced that the Canadian Patent Office has allowed Merck's patent application directed to the use of paired CRISPR nickases in eukaryotic cells.
Pangea® Laboratory announced today the licensing of a new urine-based Laboratory Developed Test (LDT) for bladder cancer detection. Commercialized and sold under the name Bladder CARE™, the test is non-invasive, cost-effective and epigenetic-based.
TC BioPharm (TCB) today announced it is collaborating with Dublin's Trinity College to accelerate in-house production of V delta 1 γδ T cell banks for treatment of solid tumors.